Clinical Trial Update: An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 trial evaluating the safety and efficacy of Atiprimod in patients with advanced cancer, sponsored by Callisto Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Atiprimod

Snippet

Sponsor: Callisto Pharmaceuticals | Conditions: Advanced Cancer | Phase 1, Phase 2 | Status: UNKNOWN